Invesco Nasdaq Biotechnology ETF (GEQ4)
XBER 
NASDAQ (NMS) Primary XBER Summary
GEQ4 Chart
5 Undervalued ETFs to Ride on Powell's Market Optimism
The Fed lifted market confidence amid economic uncertainty, leading to a rally in the U.S. stock market.
IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks
IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors should consider first. In addition to the volatile nature of the biotech industry, I'll review IBBQ's liquidity, concentration, and quality features in detail. IBBQ also has a high liquidation risk. With only $38 million in assets under management and a 0.19% expense ratio, IBBQ likely isn't a profitable product for Invesco.
Invesco Nasdaq Biotechnology ETF (GEQ4) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Invesco Nasdaq Biotechnology ETF ever had a stock split?
Invesco Nasdaq Biotechnology ETF Profile
| XBER Exchange | US Country |
Overview
The described company operates as an investment fund, primarily focusing on the securities within the biotechnology and pharmaceutical sectors as listed on the Nasdaq Stock Market. By investing at least 90% of its total assets in the components of its underlying index, the company ensures a profound commitment to the biotechnology and pharmaceutical industries. The index itself is meticulously compiled by Nasdaq, adhering to strict guidelines and procedures. It is a modified market capitalization-weighted index, aiming to represent the performance of the relevant securities in a comprehensive manner. The investment fund stands out by including companies of various sizes, ranging from large-cap to small-cap, thus enhancing its potential to capture the broad dynamics within these sectors. Notably, the fund adopts a non-diversified investment strategy, emphasizing its targeted focus within the pharmaceutical and biotechnology fields.
Products and Services
- Investment in Biotechnology and Pharmaceutical Securities
- Index-Based Investment Approach
- Exposure to Various Market Capitalizations
This service encompasses the fund's core investment strategy, which involves allocating a significant portion of its assets towards securities categorized under the biotechnology and pharmaceutical sectors in the Nasdaq Stock Market. By focusing on these areas, the fund aims to leverage the growth and innovation driving these industries.
The investment fund employs an index-based approach to investing, specifically targeting the securities that form part of its underlying index. This index is a modified market capitalization weighted index, compiled by Nasdaq, designed to capture the performance of selected companies within the biotechnology and pharmaceutical sectors. This strategy allows for structured and focused investment in accordance with predefined guidelines.
Unlike many other funds, this investment vehicle does not limit itself to companies of a certain size. Instead, it aims to provide exposure to a wider spectrum of the market by including companies of different market capitalizations, from large to small. This diversified approach within the fund’s narrow sector focus optimizes opportunities for growth across different stages of company development.
